Viatris Unveils Phase 3 Data for Presbyopia and Mesopic Vision Treatments at ASCRS 2026
Event summary
- Viatris will present four abstracts at the 2026 ASCRS Annual Meeting, including Phase 3 data for MR-141 (phentolamine ophthalmic solution) in presbyopia and MR-142 for mesopic vision disturbances.
- Key presentations include full results from the VEGA-3 study and an encore presentation of the LYNX-2 study.
- Viatris sponsored an educational symposium on presbyopia management, hosted by PRIME.
- The company holds exclusive U.S. commercialization rights for phentolamine ophthalmic solution under a global licensing agreement with Opus Genetics.
The big picture
Viatris's presentations at ASCRS 2026 highlight its focus on expanding its ophthalmology portfolio, particularly in addressing presbyopia and mesopic vision disturbances—conditions affecting millions globally. The company's strategic licensing agreement with Opus Genetics underscores its commitment to commercializing innovative treatments in this high-growth segment. The broader industry is witnessing increased investment in pharmacological solutions for age-related vision impairments, driven by an aging population and advancements in clinical research.
What we're watching
- Regulatory Pathway
- Whether the Phase 3 data for MR-141 and MR-142 will support regulatory filings and approval timelines.
- Market Adoption
- The pace at which Viatris can commercialize phentolamine ophthalmic solution in the U.S. under its exclusive rights.
- Competitive Positioning
- How Viatris's pipeline in ophthalmology will position it against competitors in the presbyopia and mesopic vision treatment space.
Related topics